4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4.7300

19-February-25 16:45:00

15 minutes delayed

Stocks

-0.1200

-2.47%

Today's range

4.7100 - 4.9700

ISIN

N/A

Source

NASDAQ

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

06 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

04 Jun 2024 08:00:01 By Nasdaq GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences

03 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

30 May 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

09 May 2024 16:05:00 By Nasdaq GlobeNewswire
4DMT to Participate in Upcoming Investor Conference

07 May 2024 08:00:01 By Nasdaq GlobeNewswire
4DMT Announces Presentations at ARVO 2024 Annual Meeting

01 May 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

28 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences

04 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT Reports Full Year 2023 Financial Results and Operational Highlights

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

12 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

06 Feb 2024 23:27:14 By Nasdaq GlobeNewswire
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

05 Feb 2024 16:05:00 By Nasdaq GlobeNewswire
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

03 Feb 2024 17:00:00 By Nasdaq GlobeNewswire
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

29 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease

23 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

04 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

21 Dec 2023 08:00:00 By Nasdaq GlobeNewswire
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

04 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.